US Patent

US10220023 — Dosing regimen for a selective S1P1 receptor agonist

Method of Use · Assigned to Actelion Pharmaceuticals Ltd · Expires 2035-12-10 · 10y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a dosing regimen for the selective S1P1 receptor agonist (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.

USPTO Abstract

The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3103 —
U-3103 —
U-3103 —
U-3103 —
U-3103 —
U-3103 —
U-3103 —
U-3103 —
U-3103 —
U-3103 —

Patent Metadata

Patent number
US10220023
Jurisdiction
US
Classification
Method of Use
Expires
2035-12-10
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.